Tuesday, 11 August 2020

ViewRay gets Korea's nod to sell radiotherapy program

19 October 2015 | News | By BioSpectrum Bureau

ViewRay gets Korea's nod to sell radiotherapy program

Singapore: ViewRay, US based medical device company, that develops advanced radiation therapy technology for the treatment of cancer has received regulatory approval from Ministry of Food and Drug Safety (MFDS), formerly known as Korean Food and Drug Administration (KFDA), to sell its ViewRay system in Korea.

"We are extremely pleased that our clinical MRI-guided radiotherapy program is underway, with the completion of our first patient treatment," said Dr Wu "The ability to visualize the tumor and surrounding soft tissues throughout treatment was unlike anything we've experienced before and will significantly enhance our ability to deliver the best care to the patients we serve."

"Receipt of Korean regulatory approval and the completion of the first international patient treatment are exciting milestones for us as we work to bring the benefits of MRI-guided radiation therapy to patients around the world," said Mr Chris A Raanes, president and chief executive officer of ViewRay. "We are particularly pleased with how quickly and easily the system went from installation to first patient treatment."

ViewRay's MRIdian system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls